Clinical Trial

Transition to KPL-387 Monotherapy Dosing & Administration Study

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.
Protocol Amendment History 4 changes
notable Trial sites expanded: 33 -> 39 locations 2026-07-10
notable Trial sites expanded: 23 -> 32 locations 2026-06-09
notable Trial sites expanded: 14 -> 23 locations 2026-05-21
notable Trial sites expanded: 6 -> 12 locations 2026-04-18
Trial Details
NCT Number NCT07288216
Lead Sponsor Kiniksa Pharmaceuticals International, plc
Collaborators: Kiniksa Pharmaceuticals, GmbH
Conditions Recurrent Pericarditis, Heart Diseases, Pericarditis
Enrollment 80 participants
Start Date 2026-03-25
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-11